OWC Pharmaceutical Research Corp (OWCP)

[FELLER]

At one point both AstraZeneca $AZN and Amgen $AMGN thought they were on to a new blockbuster as they started Phase III on brodalumab. Then it became evident the drug spurred suicidal thoughts among patients – some of whom went on to kill themselves. Amgen walked away, and after blustering about seeing it through, AstraZeneca sold it to a bottom-feeding Valeant for a mere $100 million upfront, $170 million in development milestones and $175 million in sales bonuses.

https://endpts.com/valeant-gets-an-fda-ok-for-new-psoriasis-drug-brodalumab-but-theres-a-big-catch/